Clinical trials: Genital Wart
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
External Genital Warts
Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment
External Genital Warts (EGW) are the most common sexually transmitted disease associated with more than 30 types of the Human Papillomavirus (HPV). Cryotherapy is an effective method of EGW treatment.
- Trial name
- NCT02147353
- Testing
- Sinecatechins 15% Ointment, Cryotherapy alone
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)
A study to evaluate the efficacy and tolerability of V501 (quadrivalent Human Papilloma Virus [HPV] [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine, GARDASIL™) in healthy, 16- to 26-year old Japanese males.
- Trial name
- NCT01862874
- Testing
- V501
- Volunteers
- 1,124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Condylomata Acuminata, Papillomavirus Infections
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW).
- Conditions
- Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious
- Trial name
- CARE-1 (NCT03981822)
- Testing
- VP-102 and applicator
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Genital Warts
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00674739
- Testing
- Imiquimod, 3.75% imiquimod cream
- Where
- 30 sites in United States
- Volunteers
- 470 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Anogenital Human Papilloma Virus Infection, Condyloma Acuminata
Safety and Tolerability Study of V501 in Japanese Boys (V501-200)
This is a study of V501 [quadrivalent Human Papillomavirus (HPV) (Type 6, 11, 16 and 18) L1 virus-like particle (VLP) vaccine] in healthy Japanese boys. This study will consist of two periods.
- Trial name
- NCT02576054
- Testing
- V501
- Where
- Japan
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Papillomavirus Infections
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa.
- Trial name
- NCT01245764
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00735462
- Testing
- 2.5% imiquimod cream, 3.75% imiquimod cream
- Where
- 43 sites in United States
- Volunteers
- 511 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
The purpose of this study was to evaluate the safety, efficacy, and immunogenicity of V503 in comparison to GARDASIL. The primary hypotheses tested in the study were 1) V503 administered to 16- to 26-year-old adolescents and…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00543543
- Testing
- Comparator: GARDASIL, Experimental: V503
- Volunteers
- 14,840 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus, Cervical Cancer
Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)
This study will examine the safety and tolerability of octavalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine formulated with amorphous aluminum hydroxysulfate (AAHS) and ISCOMATRIX™ (IMX).
- Conditions
- Human Papilloma Virus, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT00851643
- Testing
- Octavalent HPV with 15 mcg IMX / AAHS, Octavalent HPV with 30 mcg IMX / AAHS, Octavalent HPV with 60 mcg IMX / AAHS
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infertility
Follicular Activation in Poor Responders
This study aims to assess whether activation of primordial follicles through ovarian cortex fragmentation may increase the number of antral follicles present in the ovary of patients with diminished ovarian reserve.
- Trial name
- FAPPOR (NCT02354963)
- Testing
- In vitro fragmentation of the ovarian tissue
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- César Díaz García
Common Wart, Warts Hand
Cantharidin and Occlusion in Verruca Epithelium
This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common…
- Conditions
- Common Wart, Warts Hand, Warts, Papillomavirus Infections
- Trial name
- COVE-1 (NCT03487549)
- Testing
- VP-102 Cantharidin topical film forming solution, VP-102 Cantharidin, topical film forming solution
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Verrica Pharmaceuticals Inc.
External Anogenital Warts
Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts
A clinical endpoint bioequivalence (BE) study for a Podofilox Gel 0.5% formulation for the treatment of external anogenital warts in comparison to Condylox® Gel 0.5% that follows the study design and recommendations according to…
- Trial name
- NCT03532776
- Testing
- Podofilox Gel 0.5%, Condylox Topical Gel 0.5%
- Where
- 17 sites in United States, Russia and 1 more
- Volunteers
- 466 people
- Sponsor
- Dermax SA
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Warts, Genital, Neoplasms, Anal
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the…
- Trial name
- NCT04635423
- Testing
- V503
- Where
- 22 sites in Japan
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer, Hpv
Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
The purpose of the study is to understand if children with liver and kidney transplants develop the antibodies from the Gardasil vaccine.
- Conditions
- Cervical Cancer, Hpv, Warts
- Trial name
- NCT01101750
- Testing
- Quadrivalent HPV for types 6, 11, 16 and 18
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Medstar Health Research Institute
Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16
HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
Primary, Secondary, and Exploratory Objective(s): Primary objective: To evaluate the effect of interventions on 1st dose uptake of HPV vaccine.
- Conditions
- Human Papilloma Virus Infection Type 11, Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus Infection Type 6
- Trial name
- NCT02551887
- Testing
- Automated Reminder, Automated Reminder Plus Script
- Volunteers
- 647 people
- Sponsor
- Regenstrief Institute, Inc.
Genital Warts
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Large genital warts are frequently diagnosed in general gynaecology and oncology clinics in South Africa. Medical and destructive therapy for small warts is generally very effective, however unique problems posed by large or…
- Trial name
- TheraVACCS (NCT02750202)
- Testing
- Quadrivalent HPV vaccine, Hepatitis B vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Pretoria
HIV Positive, Anal Condylomata
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
The primary objective of this pilot study is to evaluate the effect of the HPV vaccine Gardasil on anal condylomata recurrence and persistence rates in HIV positive patients.
- Conditions
- HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
- Trial name
- NCT00941889
- Testing
- Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine